Leaked Data Boost J&J and Legend’s CAR-T Carvykti But Manufacturing Issues Remain
Risk Of Progression Or Death Cut By 74%
Executive Summary
An accidental peek at data suggests Carvykti can outperform Bristol Myers Squibb’s rival CAR-T therapy Abecma, if it can prove a survival benefit and overcome manufacturing limitations that are hampering both products.
You may also be interested in...
Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
BMS To Take Over Novartis Plant In Effort To Boost Viral Vector Production For CAR-Ts
BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.
J&J Hedges On 2025 Pharma Revenue Outlook
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.